Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Hematologic, Leukemia
II
Byrne, Michael
NCT03286530
VICCBMT1778

Sitravatinib and Nivolumab in Urothelial Carcinoma Study

The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Not Available
II
Davis, Nancy
NCT03606174
VICCURO18175

Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease

This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Not Available
II
Kitko, Carrie
NCT03846479
VICCPED1912

Rucaparib and Nivolumab in Treating Patients with Advanced or Metastatic Biliary Tract Cancer after Platinum Therapy

This phase II trial studies how well rucaparib and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body after platinum therapy. Rucaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and nivolumab after platinum therapy may help kill more cancer cells that are left after chemotherapy.
Not Available
II
Goff, Laura
NCT03639935
VICCGI1915

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients with Prostate Cancer

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Not Available
II
Planz, Virginia
NCT03697148
ECOGUROEA8171

Aspirin in Preventing Colorectal Cancer in Patients with Colorectal Adenoma

This randomized phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Not Available
II
Dai, Qi
NCT02965703
VICCGI17105

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed / refractory B-cell non-Hodgkin lymphoma (r / r B-NHL). For pediatric patients who have r / r B-NHL, survival rates are dismal, only ~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Not Available
II
Kitko, Carrie
NCT03610724
VICCPED18169

Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer

This randomized phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Due to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.
Not Available
II
Bischoff, Lindsay
NCT02393690
VICCHN1817

WAPPS- Hemo (Web Accessible Population Pharmacokinetics Service - Hemophilia)
Protocol ? Phase 2: Testing and Validation

Not Available
II
Wheeler, Allison
NCT02061072
VICCNCBH1824

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Not Available
II
Ciombor, Kristen
NCT03384940
VICCGI1825

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: